NRXP•benzinga•
NRX Pharmaceuticals' HOPE Therapeutics Signs Term Sheet With A Global Medical Device Manufacturer; The Term Sheet Contemplates An Investment Of $2.5M To Purchase Series A Convertible Preferred Stock At $50M Pre-Money Valuation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga